Some Australian pharmaceutical companies have moved to reassure investors that a new United States tariff on imported pharmaceuticals is unlikely to materially disrupt their businesses, even as the policy signals a significant shift in global trade dynamics. …
Australian companies downplay US tariff risk as CSL and Mayne signal limited impact
April 8, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Australian dementia experts push back on Cochrane Review, defending new treatments
April 20, 2026 - - Latest News -
Australia’s drug pricing dogma risks failing patients in the face of international realities
April 20, 2026 - - Latest News -
Free RSV vaccines roll out to protect senior Australians ahead of winter
April 20, 2026 - - Latest News -
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News